Fig. 4
METTL3 inhibits LUAD ferroptosis through SLC7A11 m6A modification. A KEGG pathway enrichment analysis of MeRIP-seq data. B and C Flow cytometry analysis of intracellular ROS levels measured by DFCH-DA fluorescence with transfection of METTL3 siRNA or NC siRNA in H1975 and PC9 cells (48 h), and METTL3 overexpression in H322 cells (24 h). D and E Intracellular MDA levels normalized to corresponding protein contents in METTL3 knockdown or overexpression cells. F–H) Intracellular ROS and MDA levels in METTL3 stable knockdown H1975 and PC9 cells with SLC7A11 overexpression or Fer-1 treatment (1 μM) for 48 h. I The transfection efficiency of SLC7A11 overexpression in METTL3 stable knockdown H1975 and PC9 cells was confirmed by western blot. J CCK-8 assays showed the growth curves of H1975 and PC9 cells for 3 days after indicated treatments (Fer-1, 1 μM). K Representative images of EdU staining and the ratio of EdU positive cells to total Hoechest 33342 positive cells in METTL3 stable knockdown PC9 cells after SLC7A11 overexpression or Fer-1 treatment (1 μM) for 48 h, compared with control PC9 cells (Scale bar: 100 μm). L Flow cytometry analysis for apoptotic cell proportion (Q2 + Q3) by Annexin V-FITC/PI staining. *P < 0.05, **P < 0.01, ***P < 0.001